CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Verrica Pharmaceuticals Inc. - VRCA CFD

    3.75
    0.81%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.06
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Verrica Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 3.72
    Open* 3.75
    1-Year Change* 8.38%
    Day's Range* 3.71 - 3.83
    52 wk Range 2.02-8.70
    Average Volume (10 days) 217.68K
    Average Volume (3 months) 8.86M
    Market Cap 175.83M
    P/E Ratio -100.00K
    Shares Outstanding 42.06M
    Revenue 8.61M
    EPS -0.53
    Dividend (Yield %) N/A
    Beta 2.02
    Next Earnings Date Nov 6, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 21, 2023 3.72 -0.12 -3.12% 3.84 3.88 3.66
    Sep 20, 2023 3.97 0.13 3.39% 3.84 4.12 3.84
    Sep 19, 2023 4.00 0.15 3.90% 3.85 4.02 3.83
    Sep 18, 2023 3.90 -0.09 -2.26% 3.99 4.03 3.85
    Sep 15, 2023 4.01 -0.06 -1.47% 4.07 4.13 3.96
    Sep 14, 2023 4.17 0.08 1.96% 4.09 4.25 4.01
    Sep 13, 2023 4.12 -0.14 -3.29% 4.26 4.41 4.04
    Sep 12, 2023 4.27 0.13 3.14% 4.14 4.30 4.01
    Sep 11, 2023 4.17 0.09 2.21% 4.08 4.25 4.01
    Sep 8, 2023 4.25 0.08 1.92% 4.17 4.33 4.06
    Sep 7, 2023 4.16 -0.06 -1.42% 4.22 4.22 4.08
    Sep 6, 2023 4.20 -0.13 -3.00% 4.33 4.42 4.18
    Sep 5, 2023 4.33 -0.11 -2.48% 4.44 4.56 4.32
    Sep 1, 2023 4.60 0.14 3.14% 4.46 4.76 4.34
    Aug 31, 2023 4.52 0.13 2.96% 4.39 4.59 4.33
    Aug 30, 2023 4.47 0.08 1.82% 4.39 4.52 4.36
    Aug 29, 2023 4.46 -0.03 -0.67% 4.49 4.67 4.42
    Aug 28, 2023 4.49 0.01 0.22% 4.48 4.58 4.43
    Aug 25, 2023 4.47 0.14 3.23% 4.33 4.55 4.22
    Aug 24, 2023 4.34 0.04 0.93% 4.30 4.43 4.21

    Verrica Pharmaceuticals Inc. Events

    Time (UTC) Country Event
    Monday, November 6, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 Verrica Pharmaceuticals Inc Earnings Release
    Q3 2023 Verrica Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    Monday, February 19, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Verrica Pharmaceuticals Inc Earnings Release
    Q4 2023 Verrica Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 9.032 12 0 0 0
    Revenue 9.032 12 0 0
    Total Operating Expense 31.765 42.908 40.181 30.08 21.878
    Selling/General/Admin. Expenses, Total 17.405 26.979 24.508 14.644 9.052
    Research & Development 12.198 15.929 15.673 15.436 12.826
    Operating Income -22.733 -30.908 -40.181 -30.08 -21.878
    Interest Income (Expense), Net Non-Operating -1.696 -4.172 -2.512 1.877 1.231
    Net Income Before Taxes -24.487 -35.08 -42.694 -28.207 -20.648
    Net Income After Taxes -24.487 -35.08 -42.694 -28.207 -20.648
    Net Income Before Extra. Items -24.487 -35.08 -42.694 -28.207 -20.648
    Net Income -24.487 -35.08 -42.694 -28.207 -20.648
    Income Available to Common Excl. Extra. Items -24.487 -35.08 -42.694 -28.207 -20.648
    Income Available to Common Incl. Extra. Items -24.487 -35.08 -42.694 -28.207 -20.648
    Diluted Net Income -24.487 -35.08 -42.694 -28.207 -20.648
    Diluted Weighted Average Shares 34.1634 27.0445 24.9956 24.8979 25.8099
    Diluted EPS Excluding Extraordinary Items -0.71676 -1.29712 -1.70806 -1.13291 -0.8
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -0.6747 -1.29712 -1.70806 -1.13291 -0.8
    Other, Net -0.058 -0.001 -0.004 -0.001
    Total Adjustments to Net Income 0
    Cost of Revenue, Total 0.725
    Gross Profit 8.307
    Unusual Expense (Income) 1.437
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0.182 0.037 0.068 8.319 0.214
    Revenue 0.182 0.037 0.068 8.319 0.214
    Total Operating Expense 11.798 7.126 6.279 8.308 9.335
    Selling/General/Admin. Expenses, Total 5.937 4.319 3.189 3.925 5.173
    Research & Development 5.725 2.739 2.365 2.946 4.162
    Operating Income -11.616 -7.089 -6.211 0.011 -9.121
    Interest Income (Expense), Net Non-Operating 0.626 0.5 0.286 0.067 -1.046
    Net Income Before Taxes -10.99 -6.589 -5.932 0.083 -10.168
    Net Income After Taxes -10.99 -6.589 -5.932 0.083 -10.168
    Net Income Before Extra. Items -10.99 -6.589 -5.932 0.083 -10.168
    Net Income -10.99 -6.589 -5.932 0.083 -10.168
    Income Available to Common Excl. Extra. Items -10.99 -6.589 -5.932 0.083 -10.168
    Income Available to Common Incl. Extra. Items -10.99 -6.589 -5.932 0.083 -10.168
    Diluted Net Income -10.99 -6.589 -5.932 0.083 -10.168
    Diluted Weighted Average Shares 45.9169 43.0234 41.1702 44.6562 27.5191
    Diluted EPS Excluding Extraordinary Items -0.23935 -0.15315 -0.14408 0.00186 -0.36949
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.23935 -0.15315 -0.14408 0.03404 -0.36949
    Other, Net 0 -0.007 0.005 -0.001
    Unusual Expense (Income) 0 1.437
    Cost of Revenue, Total 0.136 0.068 0.725
    Gross Profit 0.046 -0.031 -0.657
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 39.115 74.328 67.65 64.983 91.152
    Cash and Short Term Investments 34.273 70.354 65.47 62.017 89.809
    Cash & Equivalents 34.273 15.752 10.686 9.241 10.271
    Prepaid Expenses 4.355 3.974 2.18 2.966 1.343
    Total Assets 44.721 80.125 74.154 68.424 91.906
    Total Current Liabilities 3.459 46.055 39.475 3.351 2.477
    Accounts Payable 0.507 0.845 0.348 1.185 0.922
    Payable/Accrued 0.038
    Accrued Expenses 2.952 3.511 3.312 2.166 1.517
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 4.688 47.52 41.168 3.409 2.477
    Total Long Term Debt 0 0.016 0 0 0
    Total Equity 40.033 32.605 32.986 65.015 89.429
    Redeemable Preferred Stock 0
    Common Stock 0.004 0.003 0.003 0.003 0.003
    Additional Paid-In Capital 203.482 171.597 136.868 126.594 122.526
    Retained Earnings (Accumulated Deficit) -163.453 -138.966 -103.886 -61.192 -33.083
    Total Liabilities & Shareholders’ Equity 44.721 80.125 74.154 68.424 91.906
    Total Common Shares Outstanding 41.0941 27.5191 25.4411 25.807 25.7048
    Property/Plant/Equipment, Total - Net 5.33 5.502 4.938 2.201 0.255
    Other Long Term Assets, Total 0.276 0.295 1.566 1.24 0.499
    Treasury Stock - Common 0 0 0 0
    Short Term Investments 0 54.602 54.784 52.776 79.538
    Property/Plant/Equipment, Total - Gross 6.029 5.756 5.065 2.285 0.275
    Accumulated Depreciation, Total -0.699 -0.254 -0.127 -0.084 -0.02
    Other Equity, Total -0.029 0.001 -0.39 -0.017
    Other Liabilities, Total 1.229 1.449 1.693 0.058
    Current Port. of LT Debt/Capital Leases 0 41.699 35.315
    Other Current Liabilities, Total 0 0.5
    Capital Lease Obligations 0 0.016
    Total Receivables, Net 0.487
    Long Term Debt 0
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 63.097 39.115 43.395 57.341 65.772
    Cash and Short Term Investments 59.952 34.273 39.454 14.398 21.904
    Cash & Equivalents 59.952 34.273 32.473 5.43 10.407
    Short Term Investments 0 6.981 8.968 11.497
    Total Receivables, Net 0.056 0.487 0.419 0.218 0.431
    Prepaid Expenses 3.089 4.355 3.522 2.725 3.437
    Total Assets 68.639 44.721 49.147 63.436 71.617
    Property/Plant/Equipment, Total - Net 5.173 5.33 5.531 5.626 5.703
    Property/Plant/Equipment, Total - Gross 6.003 6.029 6.1 6.076 6.055
    Accumulated Depreciation, Total -0.83 -0.699 -0.569 -0.45 -0.352
    Other Long Term Assets, Total 0.369 0.276 0.221 0.469 0.142
    Total Current Liabilities 2.643 3.459 3.078 45.711 44.8
    Accounts Payable 0.575 0.507 0.137 0.714 0.531
    Accrued Expenses 2.068 2.952 2.941 2.697 2.264
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 0 42.3 42.005
    Other Current Liabilities, Total
    Total Liabilities 3.793 4.688 4.382 47.103 46.199
    Total Long Term Debt 0 0 0 0.013 0.015
    Other Liabilities, Total 1.15 1.229 1.304 1.379 1.384
    Total Equity 64.846 40.033 44.765 16.333 25.418
    Common Stock 0.004 0.004 0.004 0.003 0.003
    Additional Paid-In Capital 234.884 203.482 202.311 173.998 172.913
    Retained Earnings (Accumulated Deficit) -170.042 -163.453 -157.521 -157.604 -147.436
    Treasury Stock - Common 0 0 0 0
    Other Equity, Total -0.029 -0.064 -0.062
    Total Liabilities & Shareholders’ Equity 68.639 44.721 49.147 63.436 71.617
    Total Common Shares Outstanding 41.8521 41.0941 41.0941 27.5191 27.5191
    Capital Lease Obligations 0 0 0.013 0.015
    Other Current Assets, Total 40 40
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -24.487 -35.08 -42.694 -28.207 -20.648
    Cash From Operating Activities -18.65 -27.582 -30.207 -27.408 -17.874
    Non-Cash Items 7.183 7.789 10.809 2.463 1.816
    Cash Interest Paid 1.789 2.85 1.875 0 0
    Changes in Working Capital -1.8 -0.535 1.635 -1.728 0.938
    Cash From Financing Activities -16.87 33.646 35.232 0.423 99.376
    Financing Cash Flow Items -0.017 0 0.319 0 -7.881
    Issuance (Retirement) of Stock, Net 26.901 28.676 0.453 0.423 107.257
    Net Change in Cash 18.521 5.066 1.445 -1.03 1.608
    Cash From Operating Activities 0.454 0.244 0.043 0.064 0.02
    Cash From Investing Activities 54.041 -0.998 -3.58 25.955 -79.894
    Capital Expenditures -0.302 -0.883 -1.47 -0.682 -0.275
    Other Investing Cash Flow Items, Total 54.343 -0.115 -2.11 26.637 -79.619
    Issuance (Retirement) of Debt, Net -43.754 4.97 34.46
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -6.589 -24.487 -18.555 -18.638 -8.47
    Cash From Operating Activities -4.59 -18.65 -13.696 -15.521 -8.34
    Cash From Operating Activities 0.131 0.454 0.323 0.196 0.098
    Non-Cash Items 1.165 7.183 5.92 3.228 1.725
    Cash Interest Paid 0 1.789 1.788 1.468 0.725
    Changes in Working Capital 0.703 -1.8 -1.384 -0.307 -1.693
    Cash From Investing Activities -0.011 54.041 47.287 45.218 43.013
    Capital Expenditures -0.011 -0.302 -0.236 -0.159 -0.005
    Other Investing Cash Flow Items, Total 0 54.343 47.523 45.377 43.018
    Cash From Financing Activities 30.28 -16.87 -16.87 -0.019 -0.018
    Issuance (Retirement) of Stock, Net 30.308 26.901 26.901 0 0
    Issuance (Retirement) of Debt, Net 0 -43.754 -43.754 -0.002 -0.001
    Net Change in Cash 25.679 18.521 16.721 29.678 34.655
    Financing Cash Flow Items -0.028 -0.017 -0.017 -0.017 -0.017

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Verrica Pharmaceuticals Inc. Company profile

    About Verrica Pharmaceuticals Inc

    Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing novel treatments for skin diseases. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through single-use precision applicator. The Company is developing VP-102 for the treatment of molluscum contagiosum, or molluscum, a contagious and primarily pediatric viral skin disease, and common warts. It is conducting Phase II clinical trial for the treatment of plantar warts.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Verrica Pharmaceuticals Inc revenues increased from $0K to $12M. Net loss decreased 18% to $35.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-Based Compensation in SG&A decrease of 50% to $4.5M (expense), Research and development - Balancing val decrease of 3% to $14.4M (expense).

    Industry: Pharmaceuticals (NEC)

    10 N High St Ste 200
    WEST CHESTER
    PENNSYLVANIA 19380-3014
    US

    Income Statement

    • Annual
    • Quarterly

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    XRP/USD

    0.52 Price
    +1.110% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    US100

    14,710.90 Price
    +0.190% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    ETH/USD

    1,597.48 Price
    +0.440% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    Oil - Crude

    90.14 Price
    +0.770% 1D Chg, %
    Long position overnight fee 0.0415%
    Short position overnight fee -0.0634%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading